R&D channel feed – Endpoints News

R&D channel feed

Armed with $137M fund, Signet launches hunt for a dozen new biotech plays

9 years ago

Is Spinraza worth $750K? Biogen says yes, spelling out reduced death risk

9 years ago

Investigators signal thumbs-up for antibiotic, prep an FDA pitch for OK

9 years ago

Failed Nivalis pares down to a skeleton crew as it launches a salvage operation

9 years ago

CureVac’s lead mRNA program flunks a critical PhIIb study, raising questions for high-profile biotech unicorns

9 years ago

Daiichi Sankyo launches global R&D restructuring, looking to slash costs in an overhaul

9 years ago

In a stunner, Merck leaps ahead of rivals with combo Keytruda/chemo attack on lung cancer

9 years ago

Struggling Sarepta bounces back as analysts cheer the first trickle of revenue for DMD drug

9 years ago

Biogen CEO Michel Vounatsos regroups and stakes out a BD plan for 2017

9 years ago

Secretive? Moderna details its pipeline strategy at JPM but at least one critic bites back

9 years ago

Kite lines up a JV in China while Daiichi Sankyo strikes $250M-plus deal to launch CAR-T drug in Japan

9 years ago

Gilead tosses $100M milestone chip in its fast-growing gamble on new NASH drugs

9 years ago

Aeterna Zentaris doubles down on macimorelin PhIII, and loses

9 years ago

Arena sheds ties to weight drug Belviq, completing a makeover

9 years ago

Inotek starts off 2017 with a PhIII failure for lead drug, shares crater

9 years ago

Pfizer partner Opko reports a PhIII failure for growth hormone, but tries to steer out of a crash

9 years ago

In back-to-back disasters, the FDA spurns Innocoll’s NDA and shares plunge (again)

9 years ago

Faced with a dilemma, the FDA rejects Cempra's antibiotic, demands big safety study

9 years ago

In back-to-back failures, Anthera’s CF drug Sollpura falls short in PhIII, shares crater (again)

9 years ago

Seattle Genetics stock tumbles after 4 deaths force the FDA to slap a clinical hold on AML drug

9 years ago

Merck’s Ebola vaccine promises to stop the next outbreak in its tracks

9 years ago

Bial accused of negligence in lethal drug trial — Nature

9 years ago

Roche readies a hunt for marketing OK on hemophilia blockbuster hopeful emicizumab after PhIII success

9 years ago

Alexion adds a failed pivotal Soliris trial to an air of crisis. The perfect time to talk buyout

9 years ago

First page Previous page 307 308 309310311 312 313 Next page Last page